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This knowledge-based activity is targeted for all phannacists 
and is acceptable for 1.0 hour (0.1 CEU) of continuing 
education credit. This course requires completion 
of the program evaluation and at least a 70 percent grade 
on the program assessment questions. 
ACPE Universal Activity Number (UAN): 0048-0000-16-217-HO 1-P 
To complete the continuing education program and receive 
credit, please go to www.raabecollegeofpharmacy.org/PAW/. 
Objectives 
After completion of this program, the reader should be able to: 
1. Describe the mechanism of action and administration 
of naloxone. 
2. Identify the signs and symptoms of opioid intoxica-
tion and overdose. 
3. Recognize the emergency dispensing laws for nalox-
one. 
4. Assess the risks and effects of the changing purity of 
heroin combined with fentanyl. 
5. Define tolerance, cross-tolerance and incomplete 
cross-tolerance. 
1Abstract 
!Over the last few years, there has been an exponential in-
1crease in morbidity and mortality associated with heroin 
!abuse. The current rise in heroin abuse and overdose is 
/attributed to widespread use and abuse of prescription opi-
1oids, which can produce significant euphoric effects in bu-
/mans. In fact, reports suggest that heroin abusers initially 
/become addicted to prescription opioids but subsequently 
/switch to heroin because it is cheaper and more easily availa-
lble than prescription opioids. Over the years, the purity of 
I heroin available for illicit use has been on the decline. Smug-
jglers and heroin vendors have started mixing heroin with 
[other clandestinely prepared, potent, analgesic opioids such 
ias fentanyl. Fentanyl is 30 to 50 times more potent than her-
1oin, and the combination can be quite lethal to abusers due to 
/the increased potency and effects on the body's respiratory 
1centers which may result in death. This review will mainly 
!focus on some of the recent trends in heroin abuse and 
1recent changes in laws with respect to dispensing and pos-
1session of naloxone, an effective antidote against heroin 
[overdose. Finally, the role of the pharmacist in countering 
lthe current heroin epidemic by recognizing at-risk popula-
/tions and providing the proper resources to addicts to pre-
lvent further heroin/opioid-related overdose fatalities will be 
I discussed. 
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Introduction 
Heroin is a highly addictive drug, and over the last decade 
the abuse of heroin has resulted in a sharp rise in heroin 
overdose deaths across the United States. The National Fo-
rensic Laboratory Information System (NFLIS) collects sub-
missions from state and local forensic labs on any incidences 
that involve illicit drugs or legal drugs. From 2004 to 2014, 
heroin was consistently in the top five most commonly sub-
mitted drugs.l-11 Additionally, the rate of heroin use doubled 
from 2010 to 2012 compared to use between 2008 and 2010 
alone. Importantly, the number of deaths per 10,000 in the 
Midwest region, which includes Ohio, nearly doubled be-
tween 2010 to 2012.12 
The Drug Enforcement Agency (DEA) reports suggest a de-
crease in the purity of heroin available on the street. To 
counter this decrease in purity and enhance the potency of 
heroin, drug vendors and smugglers have started a trend of 
mixing/diluting heroin with illegally synthesized potent an-
algesics. One of the most common drugs added to heroin is 
the prescription opiate analgesic fentanyl. An increasing 
amount of fentanyl and its derivatives are being produced in 
clandestine laboratories, which are facilities that manufac-
ture illegal drugs.13,l4 Data from the NFLIS indicate that fen-
tanyl and heroin showed an overall increase in the number of 
their respective NFLIS submissions from 2004 to 2014. From 
2004 to 2013, fentanyl was submitted hundreds of times 
each year.1.10,12-19 However, from 2013 to 2014, fentanyl sub-
missions quadrupled from 942 to 4,642 cases.2,11 Figures 1 
and 2 show these trends for heroin and fentanyl submis-
sions, respectively, over the last 10 years.3 The addition of 
fentanyl to heroin provides a much greater risk of toxicity to 
the drug abuser. The combination of heroin with fentanyl has 
been largely responsible for the rapid rise in heroin overdose 
fatalities. 
The goal of this review is to discuss the history of heroin 
abuse over the decades and highlight some of the recent 
trends associated with heroin abuse. In addition, the 
pharmacologic effects of heroin and fentanyl, and the danger 
associated with their combination, will be described. Further-
more, the role of naloxone in reversing heroin intoxication, re-
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Figure 1. Number of Annual Submissions Involving Heroin to NFLIS from Various State and Local Forensic Labs.1-11 
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Figure 2. Number of Annual Submissions Involving Fentanyl to NFLIS from Various State and Local Forensic Labs. 1-11 
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cent changes in the naloxone prescription law and the role of the 
pharmacist in countering the heroin epidemic will be discussed. 
Heroin Addiction: An Historical Perspective and Chang-
ing Trends 
Heroin is chemically derived from the naturally occurring 
opioid morphine, extracted from the opium poppy plant.ls 
Bayer originally introduced heroin to the market in 1898 as a 
cough suppressant and sedative due to its superior efficacy 
over the standard morphine or codeine.16 However, by 1910, 
it became clear that heroin had the potential to be extremely 
addictive. Later in 1924, heroin production was banned by 
the U.S. Heroin Act. However, this also started the dawn of 
heroin's black-market manufacturing and abuse.17 Subse-
quent to this prohibition, the first major increase in heroin 
abuse in the United States occurred during the 1960s. This 
wave of heroin abuse correlated with the return of troops 
from the Vietnam War, who started heavily abusing heroin in 
Vietnam. The most recent wave of heroin abuse started 
around 2000, which was mainly perpetrated by the expansive 
abuse of opioid painkillers over the previous two decades. A 
large percentage of current heroin abusers actually start us-
ing prescription opioids first and then switch to heroin be-
cause it is cheaper and easier to obtain.18 
There have been a number of new reports that suggest chang-
es in the trends of heroin abuse. Previously, heroin was typi-
cally abused by nonwhite populations living in urban 
areas.18 Currently, heroin abuse has also spread to suburban 
and rural areas, predominantly among whites. In addition to 
the shift in location and race, there is also a shift seen in the 
mean age of heroin abusers. The median age of heroin abus-
ers has gone up from 16 years of age in the 1960s to 20 years 
of age in the 1980s and now has increased to 23 years of age. 
These changing trends suggest a wider, more atypical envi-
ronment in which heroin is being abused. 
Changes in Purity of Heroin 
During the wave of heroin abuse through the 1960s and 
1980s, heroin was smuggled into the United States from 
Southeast Asia, Afghanistan and Nigeria. Beginning in the 
1990s through today, most of the heroin found in the United 
States is imported from Mexico and South America.19 Current-
ly, it is recognized that there are two distinct heroin markets 
that dominate the United States. The East Coast of the United 
States normally receives most of its heroin from South Ameri-
can countries, whereas the West Coast heavily imports heroin 
from Mexico.20 Interestingly, the DEA has reported a decline 
in the purity of heroin over the last few years with an in-
crease in price per milligram of heroin. The declining purity 
in heroin has initiated a dangerous trend among vendors and 
smugglers of mixing (cutting) heroin with other drugs, such 
as fentanyl, to enhance its effects.13 Since fentanyl is a signifi-
cantly more potent opioid than heroin and morphine, the risk 
of overdose and subsequent death significantly increases, 
especially with an uneducated user.21 These fentanyl deriva-
tives are "cut" or diluted into heroin in an attempt to expand 
the quantity of the product for sale as well as shorten the 
time to the "rush" or euphoria.13 Additionally, due to its high 
potency, fentanyl acts quickly and requires only a low volume 
to achieve a high. Together, these characteristics are econom-
ically beneficial for the dealers of heroin. Yet the addition of 
fentanyl to heroin provides a much greater risk of toxicity to 
the drug abuser for several reasons including contamination 
of the drug product itself and the unpredictable additive ef-
fects of the combination of these two opioids.22.23 In fact, 
knowing how much fentanyl to add to heroin is often guess-
work. Additionally, when the user receives the product, they 
are unlikely to know how much of the drug is needed to at-
tain a high, which increases the chance of an overdose. 
Heroin and Fentanyl: Pharmacologic Mechanisms and 
Reward Pathway 
Two hydroxyl groups of morphine are replaced with less po-
lar acetyl groups in the heroin molecule, which is also known 
as diacetylmorphine (Figure 3). This makes heroin more lipo-
philic than morphine, which allows it to cross the blood-brain 
barrier faster.24 After passing the blood-brain barrier, plasma 
esterases de-acetylate heroin to monoacetylmorphine. Mono-
acetylmorphine is then hydrolyzed to morphine, which pro-
duces its agonistic effects on opioid receptors, initiating the 
sensation of euphoria. Heroin may be administered via nasal 
inhalation, oral smoke inhalation or intravenous injection.ts 
Although intravenous injection has the fastest onset of action, 
the drug rapidly produces euphoric effects by any administra-
tive technique. When injected intramuscularly, euphoria is 
attained after a few minutes, compared to the few seconds 
taken by intravenous injection.zs If inhaled by smoking or 
sniffing, euphoria arises after approximately 15 minutes. The 
initial euphoric high usually lasts 45 seconds to several 
minutes, but the general feeling of well-being continues three 
to five hours after administration depending on the level of 
drug potency or abuser tolerance.26 
Figure 3. Chemical Structures of Morphine, Heroin and Fentanyf.23 
CH,CH6f:fC()' 
Morphine Heroin Fentanyl 
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Fentanyl is a synthetic opioid that is frequently used in veter-
inary and human practice. It is also used in both the inpatient 
hospital and outpatient settings.20,27 Fentanyl has many de-
rivatives which include alfentanil, sufentanil, remifentanil 
and carfentanil. These derivatives can be administered by 
injection, transdermal patch or transmucosal lozenge.27 Typi-
cally, fentanyl or its derivatives are used as anesthetics ad-
junct to general anesthesia during surgery and analgesics for 
chronic pain relief or preoperative pain. Additionally, fenta-
nyl is used to treat severe pain often associated with trauma, 
burns, orthopedic conditions and terminal illness; it also re-
duces cough and diarrhea.19 Fentanyl and other opioids are 
preferred in the clinical setting because they do not cause 
loss of consciousness, euphoria or sedation when used for 
analgesia.19,2s The benefits seen in patients that use fentanyl 
or its derivatives include, but are not limited to, the follow-
ing: decreased amounts of adverse reactions, higher patient 
satisfaction, higher quality oflife, improved compliance and a 
decreased need of rescue medications. Adverse drug reac-
tions are usually only experienced when fentanyl is abused.28 
A review study done by Kornick et al. found that the benefits 
of using fentanyl as a prescription medication outweigh its 
potential risks.28 
Fentanyl is estimated to be 30 to 50 times more potent than 
heroin and between 50 to 100 times more potent than mor-
phine.19-21 This increased potency of fentanyl makes it lethal 
even at low doses.21 The lethal dose of fentanyl is estimated 
to be 2 mg in humans.27 Due to the low lethal levels of fenta-
nyl, it is very easy for a patient or a drug abuser to overdose 
on this medication. As it is often mixed with other drugs to 
produce a more powerful and dangerous street drug, there is 
an increased incidence of drug overdose with fentanyl use.20 
The actions of morphine, heroin, fentanyl and other opioid 
analgesics are mediated primarily by binding to the mu opi-
oid receptors in the neurons of the brain, spinal cord and 
gastrointestinal tract.23,29 These mu opioid receptors are 
G proteins coupled to adenylyl cyclase. Binding of the opioid 
to these receptors inhibits the production of adenylyl cyclase, 
blocking calcium ion channels and opening potassium ion 
channels in the neuron to inhibit neurotransmitter release.30 
The euphoric effects of opioids, including heroin, are mediat-
ed by mesolimbic dopaminergic neurons, which originate 
from the ventral tegmental area in the midbrain.31 The activi-
ty of these dopaminergic neurons are regulated by inhibitory 
gamma-amino-butyric acid (GABA) neurons. When an opioid 
such as morphine acts on the mu opioid receptor, the result 
is the inhibition of GABA release at synapses thus decreasing 
GABA's inhibitory effect on dopaminergic neurons. Without 
GABA-mediated inhibition, dopamine release is uninhibited 
at dopaminergic neuron terminals in areas of the brain asso-
ciated with brain reward, such as the nucleus accumbens, 
producing a sensation of euphoria. 
Mu opioid receptor agonists cause a variety of other physio-
logical reactions including respiratory depression, slowing of 
gastrointestinal movement causing constipation and brady-
cardia.29 The most life-threatening of effects is depression of 
the respiratory centers, which are located in the medulla of 
the brain stem. A reduction in glutamate-induced excitation 
decreases respiratory activity, which leads to a decreased 
sensitivity to changes in oxygen and carbon dioxide 
levels. 29,32 Decreased sensitivity to levels of these gases re-
sults in hypoventilation causing hypoxia in tissues and ulti-
mately leading to brain and subsequent organ shutdown and 
death in an overdose situation. If an overdose is survived, the 
prolonged lack of oxygen to the brain may cause severe brain 
damage. 
When opioids are combined, the effects may be additive or 
synergistic.23 When morphine is combined with fentanyl, the 
analgesic effect is increased from that of either drug alone by 
at least twofold. In one study, morphine combined with fen-
tanyl increased analgesia in mice from 10 percent with only 
morphine, and 15 percent with only fentanyl, to 30 percent 
when combined. The increased effects from combining opi-
oids have highly unpredictable effects in vivo due to its illegal 
production and, therefore, cause severe increases in fatalities 
due to overdose.33 
Opioid Tolerance, Cross-tolerance and Incomplete Cross-
tolerance 
Chronic use of opioids leads to tolerance, meaning that an 
increasingly higher dose is necessary to have the same ef-
fects as previous exposures.34 With repeated activation of the 
mu opioid receptors, as in heroin or fentanyl abuse, the mu 
opioid receptors either undergo desensitization, down-
regulation or receptor internalization. Losing opioid recep-
tors due to these three pathways decreases the number of 
receptors available to cause a response. This phenomenon is 
called tolerance.31 As a consequence, using the same dose of 
an opioid (e.g., heroin) will no longer produce the same eu-
phoria. Additionally, tolerance can develop through any 
route of administration of an opioid. 
In addition to tolerance, opioid abuse can be complicated by 
issues of cross-tolerance and incomplete cross-tolerance.23 
Cross-tolerance is the state of being tolerant to different 
chemicals or drugs that act on the same receptor. All opioids 
acting via the mu opioid receptors exhibit cross-tolerance to 
each other at varying degrees. Incomplete cross-tolerance 
occurs when tolerance to one drug is developed, but another 
drug that acts on the same receptor does not develop toler-
ance and produces normal effects. This second drug that the 
body is not yet tolerant to can be used at a much smaller 
dose, which may be useful in minimizing side effects. Howev-
er, the risk for deadly overdose greatly increases. Due to the 
unpredictable nature of incomplete cross-tolerance of opi-
oids, the risk of overdose is increased when two different 
opioids are coadministered that act on the same receptor. 
For example, consider the coadministration of morphine and 
methadone which both act on the mu receptor. A person tol-
erant to morphine would need a significantly higher dose of 
morphine compared to a drug-naive individual to produce an 
analgesic effect. In contrast, the person would still be respon-
sive to a normal dose of methadone due to incomplete cross-
tolerance. Use of methadone doses equivalent to high 
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morphine doses would cause an overdose in this particular 
patient. As heroin and fentanyl both act on the mu opioid 
receptor, incomplete cross-tolerance is a possible conse-
quence of using the two together and can increase incidences 
of overdose. 
Mortality Due to Heroin Overdose 
Between 2000 and 2013, the incidences of heroin overdose 
and death increased across the United States.20 A recent 
study of 28 states (AL, AZ, CO, FL, IL, IN, IA, KS, KY, MA, MI, 
MN, MO, MT, NE, NV, NH, NM, NY, NC, OH, OK, OR, RI, SC, UT, 
VA, WA) confirmed that the rate of heroin use increased from 
2008 to 2012, with the rate doubling between 2010 and 
Figure 4. The Number of Heroin Overdose Deaths Based 
on Gender.12 
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Figure 5. The Number of Heroin Overdose Deaths Based 
on Race/Ethnicity.12 
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2012. Overall, the data from the 28 states analyzed in this 
study encompassed 56 percent of the population of the Unit-
ed States and indicated that there is a growing problem with 
heroin mortality in the country.12 Importantly, the largest 
number of deaths from heroin overdose was seen in two dif-
ferent populations: males and whites. Figures 4 through 7 
depict various trends in heroin mortality per 100,000 people 
from 2008 to 2012.12 
Reversal of Heroin Intoxication/Overdose with Naloxone 
Symptoms of heroin intoxication are grouped into what is 
known as the "opioid triad."35 The triad of symptoms in-
cludes pinpoint pupils, unconsciousness and respiratory de-
Figure 6. The Number of Heroin Overdose Deaths Based 
onAge.12 
Number o! Overdose Deaths Per 100,0CO By Age 
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Figure 7. The Number of Heroin Overdose Deaths Based 
on Geographical Location in the United States,12 
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pression (Figure 8), which is defined as less than 12 breaths 
per minute. Naloxone (Narcan®), an opioid-receptor antago-
nist, has the highest affinity for the mu opioid receptor.36 It 
acts as an effective antidote to opioid overdoses, thus revers-
ing the effects of opioid drugs such as fentanyl and heroin. 
Naloxone has many forms of administration including in-
tranasal inhalation, intramuscular (IM) injection, intravenous 
(IV) injection undiluted by IV push, IV continuous injection 
diluted in 5 percent dextrose in water (DSW) or normal sa-
line (NS) 4 to 8 mcg/mL, or subcutaneously (SC) into the 
thigh.37 Intranasal administration of naloxone has several 
advantages including low risk of exposure to blood because 
there is no needle, fast administration, rapid onset of action, 
requires little training for administrator and is extremely 
effective. 38·39 
Figure 8. The Opioid Triad of Intoxication (Opioid 
Overdose Symptoms).35 
Pinpoint Pupils 
Respiratory 
Depression 
Unconsciousness 
Naloxone begins to have effects on the body in two to five 
minutes depending on the route of administration and has a 
30 to 90 minute duration of action. Administrators of the 
drug should remain with the patient for the 30 to 90 minute 
period in the event that readministration is required.4D Ac-
cording to the algorithms for Advanced Cardiac Life Support 
(ACLS) protocols, the initial dose ranges from 0.4 to 2 mg/mL 
and is given every two to three minutes until the desired out-
come is reached to treat opioid overdoses.41 Up to 10 mg 
is given as a total dose because the mechanism of action is 
short-lived, and repeated doses may be required depending 
on the opioid drug being antagonized. Doses should be re-
peatedly given until breathing has increased from none to 
minimal breathing. There is no tolerance buildup or abuse 
potential for naloxone. 
Side effects of naloxone when reversing opioid use include 
nausea, vomiting, sweating and tachycardia.36,37.41 As nalox-
one does not have any drug-drug interactions and is safe for 
pregnant women, it is fairly safe to give when an opioid over-
dose is suspected but not confirmed. If there is no opiate ago-
nist present in the body, naloxone will have no effect on the 
body, thus no harm would occur if a patient was misdiag-
nosed with an opioid overdose and given naloxone. When an 
opioid overdose is suspected, emergency medical services 
should be contacted immediately after a witness administers 
naloxone (or in concurrence if there is another witness avail-
able to do so) to have the best chance for the patient survival. 
Candidates to be considered for naloxone treatment include 
patients with a history of opioid overdose, a suspected histo-
ry of nonmedical opioid use, receiving high-dose opioid pre-
scriptions, receiving the first prescription for an opioid sub-
stance, receiving buprenorphine treatment for addiction, on 
opioid prescriptions with respiratory illnesses, with limited 
access to emergency medical services or by patient request.42 
Additionally, as health care professionals, pharmacists and 
prescribers are considered to be part of the at-risk communi-
ty for abuse because of easy access to prescription drugs, es-
pecially opioids. It is estimated that 10 to 15 percent of health 
care professionals are addicted to drugs or alcohol. 
As of 2014, over 150,000 people in the United States are 
trained and have received naloxone kits. Those involved with 
the training have already reported having a positive impact 
on over 26,000 overdoses nationwide.43 The kits come in two 
formulations: intranasal and intramuscular. The intranasal kit 
includes two naloxone 2 mg/2 ml prefilled syringes and two 
atomizers, while the intramuscular kit includes two naloxone 
0.4 mg/ml vials and two intramuscular syringes. Both of the 
kits contain step-by-step instructions for responding to an 
opioid overdose and directions for naloxone administration. 
The kits are to be stored at room temperature and protected 
from light; kits cannot be stored in places that are susceptible 
to seasonal temperature changes, such as a vehicle, in order 
to maintain effectiveness. Each kit has a shelf life between 12 
and 18 months, and syringes should not be filled until the 
drug is needed. Each intramuscular kit costs roughly $44 and 
intranasal kits cost around $40, which is fairly inexpensive 
compared to other means of medical treatment that would be 
involved if naloxone was not received in an overdose situa-
tion. It is estimated that annual medical costs resulting from 
opioid overdose reach $72 billion.43-45 Although these kits are 
available to first medical response teams, depending on state 
laws, bystanders, family /friends of drug abusers, and phar-
macies are also permitted to possess naloxone kits and dis-
tribute them. The laws regarding who is allowed to possess 
naloxone across the country, and which states have legisla-
ture providing immunity to individuals seeking treatment or 
providing treatment, is shown in Figure 9.43.46 
Dispensing Laws for Naloxone 
As of July 22, 2015, section 4729.44 of the Ohio Revised Code 
and rule 4 729-5-39 of the Ohio Administrative Code 
authorizes a pharmacist or pharmacy intern, under the direct 
supervision of a pharmacist, to dispense naloxone without a 
prescription to the following in accordance with a physician -
approved protocol: (1) An individual who there is reason to 
believe is experiencing or at risk of experiencing an opioid-
related overdose; (2) A family member, friend, or other per-
son in a position to assist an individual who there is reason to 
believe is at risk of experiencing an opioid-related overdose; 
or (3) A peace officer as defined in section 2921.51 of the Re-
vised Code.47 
These new amendments come with little to no negative ef-
fects and are extremely inexpensive. Even while inexpensive, 
the amendments also save health care dollars in the treat-
ment aspect. It has been estimated that annually overdose 
fatalities cost about 21.5 million.48 
Spring 2016 Volume 7, Issue 2 THE PHARMACY AND WELLNESS REVIEW 7 
Drug Abuse Latest Trends in the Heroin Epidemic and the Responsibility of the Pharmacist in Controlling Heroin Abuse 
Figure 9. The Naloxone Dispensing Laws According to State Practice. 43,46 
States in blue are those with naloxone access and drug overdose Good Samaritan laws. States in green are those with nalox-
one access laws only. States in yellow are those without either law. 
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In the past, prescribers have been concerned about "third 
party prescribing" liability; third party prescribing means the 
prescription is written for a patient who has not been evalu-
ated by a prescribing order (a standing order). Additionally, 
witnesses to overdose situations may not want to call for 
medical assistance in fear of legal punishment. Those wit-
nesses, who do realize the need for naloxone distribution and 
have the antidote on hand, may choose not to distribute it 
because of liability concern myths (i.e., witness thinks he/she 
will be prosecuted for administering incorrectly). Initial evi-
dence from the state of Washington, which amended its law 
in 2010, is positive with 88 percent of surveyed drug users 
indicating that they would be more likely to summon emer-
gency personnel during an overdose as a result of the legal 
change.43 Because of these major concerns and fears, the new 
dispensing laws have aimed to displace those fears and es-
tablish grounds for saving the lives of the victims. 
The new dispensing laws focus on two goals: 
1. The first goal is "Good Samaritan" dispensing, which en-
courages witnesses of an overdose incident to come for-
ward and get help for the victim without fear of being 
arrested for illicit drug possession. According to the Na-
tional Conference of State Legislatures, the so-called 
"Good Samaritan" laws regarding drug overdoses fall 
into two primary categories.43 The first encourages 
calling 911 to seek medical assistance for yourself or 
Opioid antagonist access and 
overdose immunity laws 
• States with opioid antagonist 
laws only 
• Slales with Good Samaritan 
overdose immunity laws and 
opioid antagonist access laws 
Slates withoul opioid anlagonist 
access laws 
crnted with mapchart.net C> 
someone experiencing an overdose by providing crimi-
nal immunity for both the person in need and the person 
who sought help. "New Mexico became the first state to 
amend its laws to encourage Good Samaritans to sum-
mon aid in the event of an overdose. As of June 22, 2016, 
thirty-five other states and the District of Columbia" 
follow the Good Samaritan law.43,46 
2. The second goal provides varying levels of criminal or 
civil immunity for those involved with the prescription, 
possession or emergency administration of the naloxone 
to reverse the effects of an overdose. 46 After the clarifica-
tion of legal immunity for those reporting an overdose, 
several states began to make moves to incorporate new 
laws to protect those reporting the overdose. Additional-
ly, prescribers would not be held liable for writing nalox-
one prescriptions for patients they did not personally 
evaluate.43 This goal strives to provide wider use and 
prescribing of naloxone. It will allow prescribers to 
confidently prescribe naloxone without fear of legal re-
percussion. Depending on the state the pharmacist and 
patient is living in, the laws for administration will vary. 
For example, in Ohio, House Bill 170 (passed on March 
11, 2014) removed civil liability for prescribers, allowed 
for third party prescriptions, removed civil liability for 
lay administration, removed criminal liability for 
prescribers and lay administration and allowed lay ad-
ministration to practice unauthorized practice of medi-
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pharmacists to distribute naloxone with less liability con-
cerns in emergency situations. Pharmacists have a responsi-
bility to be informed on the latest dispensing laws of nalox-
one in their state of practice in the event of an emergency 
overdose situation. Additionally, being knowledgeable about 
the signs and symptoms of heroin overdose and identifying 
at-risk patient populations will allow lifesaving interventions 
to be made available in a timely manner to prevent fatal hero-
in overdoses. 
cine.47.49 This means that, in a given emergency situation 
of opioid overdose, actions taken by witnesses and health 
care professionals are not prosecutable, thus encourag-
ing each participant involved to do what is best to save 
the victim's life. Currently, Ohio does not have a state 
program created and does waive criminal liability for 
possession of naloxone without a prescription. Laws spe-
cific to each state are shown in Figure 9.43,46 
Ohio offers an educational program called Project DAWN, 
which is a community-based education program that distrib-
utes naloxone for opioid overdose cases. Participants in the 
program are given intranasal naloxone when appropriate and 
receive educational training on the signs and symptoms of an 
overdose and how to administer naloxone.so 
Role of the Pharmacist 
The pharmacist's role in protecting patients from an opioid 
overdose is imperative. Pharmacists are involved in the pre-
vention of overdoses by researching patient history for the 
use of analgesics, especially opioids, using the Ohio Automat-
ed Rx Reporting System (OARRS), or state equivalent report-
ing system accordingly, and evaluating the patient's potential 
for opioid abuse. By identifying patients and health care pro-
fessionals at risk for overdoses, pharmacists can potentially 
prevent overdoses before they occur. Additionally, they can 
identify certain groups of patients with an increased risk of 
addiction to opioids, such as those with major depressive dis-
order, bipolar disorder, anxiety disorders, etc.49 
To help prevent overdoses and addiction, pharmacists should 
counsel patients on the use of opioids and the potential for 
addiction at the start of a new prescription and with every 
refill on the medication. If the patient is having a family mem-
ber or friend pick up the prescription for them, the pharma-
cist should counsel the individual picking up the medication, 
and provide hard copy medication guides to give to the pa-
tient to explain the main concerns and counseling points. It is 
also the responsibility of the pharmacist to be informed on 
the most recent state laws for distributing naloxone in their 
location of practice. This information can be found online at 
the Network for Public Health. Pharmacists should know the 
symptoms for abuse and overdose and know how to adminis-
ter naloxone in an emergency situation. The main focus of the 
pharmacist should be to provide information regarding post-
overdose treatment as well as guidance in recovering from an 
addiction. In the state of Ohio, pharmacists can refer patients 
to Project DAWN locations in order to receive community-
based encouragement, education and training on how to cope 
with and avoid overdoses. so 
Conclusion 
Overdoses as a result of heroin and other opioid medications 
kill thousands of patients annually. The dangerous trend of 
mixing clandestinely-prepared fentanyl derivatives with her-
oin has further increased the incidence of heroin overdose. 
These deaths can be prevented with lifesaving medication 
naloxone along with the timely summoning of emergency 
responders. Amended dispensing laws for naloxone allow 
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Assessment Questions 
1. Which of the following corresponds to the concept of 
incomplete cross-tolerance? 
A Higher dose of same drug is necessary to 
achieve same high. 
B. Physical reaction is the same for two different 
drugs that act on the same receptor. 
C. Tolerance to one drug is developed, but another 
drug that acts on the same receptor produces 
normal effects. 
D. Drugs acting on different receptors produce the 
same effect. 
2. Due to the high potency of fentanyl, it requires a low vol-
ume to achieve a high. This is not economically beneficial 
to the dealers of heroin. 
A True 
B. False 
3. Addition offentanyl to heroin enhances heroin's effect of 
respiratory depression. 
A. True 
B. False 
4. No matter the route of heroin administration, euphoria is 
achieved quickly. The initial euphoric high lasts--~ 
but the general feeling of well-being lasts ___ . 
A. 45 seconds to several minutes, 3 to 5 hours 
B. 30 minutes to 1 hour, 8 to 12 hours 
C. 1 to 2 hours, 18 to 24 hours 
D. 15 seconds, 8 to 12 hours 
5. Naloxone begins to have effects on the body in __ 
minutes depending on the route of administration, and 
__ minute duration of action. 
A. 10-15; 45-60 
B. 2-5; 30-90 
c. 1-2; 60-90 
D. 2-5; 60-90 
6. Which of the following is not a symptom of the Opioid 
Triad of Intoxication? 
A. Respiratory depression 
B. Unconsciousness 
C. Pinpoint pupils 
D. Tachycardia 
7. According to new law amendments, some states provide 
varying levels of criminal or civil immunity for those in-
volved with the prescription, possession, or emergency 
administration of naloxone and/ or criminal immunity 
for both the victim and the witness when seeking help by 
reporting an overdose. 
A True 
B. False 
8. According to the algorithms for Advanced Cardiac Life 
Support (ACLS) protocols, the initial dose ofnaloxone 
ranges from __ and is given every __ until the 
desired outcome is reached to treat opiate overdoses. 
A. 0.4-2 mg/mL; 2-3 minutes 
B. 2-10 mg/mL; 2-3 minutes 
C. 0.4-2 mg/mL; 10-12 minutes 
D. 2-10 mg/mL; 10-12 minutes 
9. What is the name of the educational program in Ohio 
that offers a community-based education and naloxone 
distribution center for overdose cases? 
A. Good Samaritan Outreach 
B. OARRS 
C. Project DAWN 
D. DSM 5 
10. In 2012 the __ United States had the highest number 
of heroin overdoses, and in 2012 the __ United States 
had the lowest number of heroin overdoses. 
A. midwestern; southern 
B. northeastern; western 
C. northeastern; southern 
D. southern; midwestern 
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